Cost effectiveness of sirolimus-eluting stents compared with bare metal stents in acute myocardial infarction View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2009-03

AUTHORS

Florence Canoui-Poitrine, Grégoire Jeanblanc, Corinne Alberti, Priscilla Armoogum, Ana Cebrian, Didier Carrié, Patrick Henry, Emmanuel Teiger, Michel Slama, Christian Spaulding, Isabelle Durand-Zaleski

ABSTRACT

BackgroundDrug-eluting stents have been shown to reduce the rate of repeat revascularization after percutaneous coronary intervention for acute myocardial infarction (AMI) as compared with bare metal stents (BMS). A few studies have reported the cost effectiveness of sirolimus-eluting stents (SES) in several countries, but none in the particular setting of AMI in France.ObjectivesTo assess the cost effectiveness of SES compared with BMS in a pre-specified subgroup of French patients with AMI in the randomized, multicentre TYPHOON trial.MethodsA prospective economic evaluation was conducted for the 337 patients in the TYPHOON trial who were enrolled in the French centres. In the TYPHOON trial, patients with AMI with ST-segment elevation less than 12 hours after the onset of chest pain were randomized to undergo percutaneous coronary intervention with either SES or BMS. Data on clinical outcomes and resource use were collected prospectively over a 1-year follow-up period (from October 2003 to October 2005). Unit costs were applied to the resource utilization data. The main outcome measure was the incremental cost-effectiveness ratio (ICER) for additional cost per target-vessel revascularization (TVR) avoided. The perspective of the study was the French healthcare system and costs were expressed in 2007 values.ResultsSES significantly reduced the rate of TVR (6.6% vs 22.2% with BMS, p < 0.0001). There was no difference in the rate of death, recurrent myocardial infarction or stent thrombosis after 1 year of follow-up between the SES and BMS groups. Mean index admission costs, including the angioplasty procedure, were increased by €1282 per patient in the SES group, mostly driven by the price of the SES. Mean follow-up costs were €140 per patient lower in the SES group. Mean aggregate 1-year costs showed a €1142 per-patient increase in the SES group compared with the BMS group. The ICER was €7321 per TVR avoided.ConclusionIn this pre-specified subgroup analysis of the TYPHOON trial, the use of SES in patients with AMI with ST-segment elevation less than 12 hours after the onset of chest pain reduced the rate of TVR compared with BMS. However, SES had a debatable ICER for the payer if it was based only on the specific benefit of TVR avoided. More... »

PAGES

19-29

References to SciGraph publications

  • 2006-05. Cost Effectiveness of the Sirolimus-Eluting Stent in High-Risk Patients in Canada in AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/bf03256139

    DOI

    http://dx.doi.org/10.1007/bf03256139

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1007754942


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Public Health and Health Services", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Universit\u00e9 de Lyon, Hospices Civils de Lyon, Lyon, France", 
              "id": "http://www.grid.ac/institutes/grid.413852.9", 
              "name": [
                "Assistance Publique - Hopitaux de Paris (AP-HP), Henri Mondor Hospital, EA 4393, Paris 12 Medical School, Cr\u00e9teil, France", 
                "Universit\u00e9 de Lyon, Hospices Civils de Lyon, Lyon, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Canoui-Poitrine", 
            "givenName": "Florence", 
            "id": "sg:person.01012106505.90", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012106505.90"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Assistance Publique - Hopitaux de Paris (AP-HP), Henri Mondor Hospital, EA 4393, Paris 12 Medical School, Cr\u00e9teil, France", 
              "id": "http://www.grid.ac/institutes/grid.412116.1", 
              "name": [
                "Assistance Publique - Hopitaux de Paris (AP-HP), Henri Mondor Hospital, EA 4393, Paris 12 Medical School, Cr\u00e9teil, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Jeanblanc", 
            "givenName": "Gr\u00e9goire", 
            "id": "sg:person.01317466507.22", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317466507.22"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "INSERM, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.7429.8", 
              "name": [
                "AP-HP, Unit of Clinical Epidemiology, Robert Debre Hospital, Paris, France", 
                "INSERM, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Alberti", 
            "givenName": "Corinne", 
            "id": "sg:person.01132547050.16", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132547050.16"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "AP-HP, Unit of Clinical Epidemiology, Robert Debre Hospital, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.413235.2", 
              "name": [
                "AP-HP, Unit of Clinical Epidemiology, Robert Debre Hospital, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Armoogum", 
            "givenName": "Priscilla", 
            "id": "sg:person.01047345157.34", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047345157.34"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Cordis (Johnson & Johnson), Waterloo, Belgium", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Cordis (Johnson & Johnson), Waterloo, Belgium"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Cebrian", 
            "givenName": "Ana", 
            "id": "sg:person.01133236474.84", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133236474.84"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Rangueil Hospital, Toulouse, France", 
              "id": "http://www.grid.ac/institutes/grid.414295.f", 
              "name": [
                "Rangueil Hospital, Toulouse, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Carri\u00e9", 
            "givenName": "Didier", 
            "id": "sg:person.01015234324.86", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01015234324.86"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "AP-HP, Lariboisiere-Saint Louis Hospital, Paris 7 Medical School, Denis Diderot University, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.50550.35", 
              "name": [
                "AP-HP, Lariboisiere-Saint Louis Hospital, Paris 7 Medical School, Denis Diderot University, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Henry", 
            "givenName": "Patrick", 
            "id": "sg:person.01340323437.03", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340323437.03"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Assistance Publique - Hopitaux de Paris (AP-HP), Henri Mondor Hospital, EA 4393, Paris 12 Medical School, Cr\u00e9teil, France", 
              "id": "http://www.grid.ac/institutes/grid.412116.1", 
              "name": [
                "Assistance Publique - Hopitaux de Paris (AP-HP), Henri Mondor Hospital, EA 4393, Paris 12 Medical School, Cr\u00e9teil, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Teiger", 
            "givenName": "Emmanuel", 
            "id": "sg:person.01147423204.29", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01147423204.29"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "AP-HP, Antoine Beclere Hospital, Paris 11 Medical School, Paris Sud University, Clamart, France", 
              "id": "http://www.grid.ac/institutes/grid.413738.a", 
              "name": [
                "AP-HP, Antoine Beclere Hospital, Paris 11 Medical School, Paris Sud University, Clamart, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Slama", 
            "givenName": "Michel", 
            "id": "sg:person.01307107653.82", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307107653.82"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "INSERM U 907, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.7429.8", 
              "name": [
                "AP-HP, Cochin Hospital, Paris Descartes University, Paris, France", 
                "INSERM U 907, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Spaulding", 
            "givenName": "Christian", 
            "id": "sg:person.0701250526.43", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701250526.43"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Service de Sante Publique, H\u00f4pital Henri Mondor, 51, Avenue du Mar\u00e9chal de Lattre de Tassigny, 94010, Cr\u00e9teil, Cedex, France", 
              "id": "http://www.grid.ac/institutes/grid.412116.1", 
              "name": [
                "Assistance Publique - Hopitaux de Paris (AP-HP), Henri Mondor Hospital, EA 4393, Paris 12 Medical School, Cr\u00e9teil, France", 
                "Service de Sante Publique, H\u00f4pital Henri Mondor, 51, Avenue du Mar\u00e9chal de Lattre de Tassigny, 94010, Cr\u00e9teil, Cedex, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Durand-Zaleski", 
            "givenName": "Isabelle", 
            "id": "sg:person.01327533357.46", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327533357.46"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.2165/00129784-200606030-00003", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028254639", 
              "https://doi.org/10.2165/00129784-200606030-00003"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2009-03", 
        "datePublishedReg": "2009-03-01", 
        "description": "BackgroundDrug-eluting stents have been shown to reduce the rate of repeat revascularization after percutaneous coronary intervention for acute myocardial infarction (AMI) as compared with bare metal stents (BMS). A few studies have reported the cost effectiveness of sirolimus-eluting stents (SES) in several countries, but none in the particular setting of AMI in France.ObjectivesTo assess the cost effectiveness of SES compared with BMS in a pre-specified subgroup of French patients with AMI in the randomized, multicentre TYPHOON trial.MethodsA prospective economic evaluation was conducted for the 337 patients in the TYPHOON trial who were enrolled in the French centres. In the TYPHOON trial, patients with AMI with ST-segment elevation less than 12 hours after the onset of chest pain were randomized to undergo percutaneous coronary intervention with either SES or BMS. Data on clinical outcomes and resource use were collected prospectively over a 1-year follow-up period (from October 2003 to October 2005). Unit costs were applied to the resource utilization data. The main outcome measure was the incremental cost-effectiveness ratio (ICER) for additional cost per target-vessel revascularization (TVR) avoided. The perspective of the study was the French healthcare system and costs were expressed in 2007 values.ResultsSES significantly reduced the rate of TVR (6.6% vs 22.2% with BMS, p < 0.0001). There was no difference in the rate of death, recurrent myocardial infarction or stent thrombosis after 1 year of follow-up between the SES and BMS groups. Mean index admission costs, including the angioplasty procedure, were increased by \u20ac1282 per patient in the SES group, mostly driven by the price of the SES. Mean follow-up costs were \u20ac140 per patient lower in the SES group. Mean aggregate 1-year costs showed a \u20ac1142 per-patient increase in the SES group compared with the BMS group. The ICER was \u20ac7321 per TVR avoided.ConclusionIn this pre-specified subgroup analysis of the TYPHOON trial, the use of SES in patients with AMI with ST-segment elevation less than 12 hours after the onset of chest pain reduced the rate of TVR compared with BMS. However, SES had a debatable ICER for the payer if it was based only on the specific benefit of TVR avoided.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/bf03256139", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1031175", 
            "issn": [
              "1175-5652", 
              "1179-1896"
            ], 
            "name": "Applied Health Economics and Health Policy", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "7"
          }
        ], 
        "keywords": [
          "target vessel revascularization", 
          "sirolimus-eluting stents", 
          "incremental cost-effectiveness ratio", 
          "acute myocardial infarction", 
          "bare metal stents", 
          "rate of TVR", 
          "percutaneous coronary intervention", 
          "ST-segment elevation", 
          "myocardial infarction", 
          "chest pain", 
          "coronary intervention", 
          "SES group", 
          "BMS group", 
          "metal stents", 
          "pre-specified subgroup analysis", 
          "index admission costs", 
          "pre-specified subgroups", 
          "recurrent myocardial infarction", 
          "main outcome measures", 
          "rate of death", 
          "cost-effectiveness ratio", 
          "resource utilization data", 
          "cost effectiveness", 
          "repeat revascularization", 
          "French healthcare system", 
          "clinical outcomes", 
          "prospective economic evaluation", 
          "stent thrombosis", 
          "subgroup analysis", 
          "French centers", 
          "admission costs", 
          "outcome measures", 
          "patients increases", 
          "angioplasty procedures", 
          "French patients", 
          "patients", 
          "infarction", 
          "utilization data", 
          "stents", 
          "trials", 
          "healthcare system", 
          "revascularization", 
          "pain", 
          "use of SS", 
          "intervention", 
          "economic evaluation", 
          "group", 
          "onset", 
          "elevation", 
          "hours", 
          "Randomized", 
          "thrombosis", 
          "BackgroundDrug", 
          "specific benefits", 
          "follow", 
          "ConclusionIn", 
          "resource use", 
          "ObjectivesTo", 
          "death", 
          "rate", 
          "outcomes", 
          "subgroups", 
          "payers", 
          "particular setting", 
          "study", 
          "additional cost", 
          "resultss", 
          "years", 
          "setting", 
          "use", 
          "effectiveness", 
          "period", 
          "data", 
          "differences", 
          "unit cost", 
          "evaluation", 
          "center", 
          "benefits", 
          "measures", 
          "increase", 
          "procedure", 
          "ratio", 
          "countries", 
          "cost", 
          "analysis", 
          "values", 
          "France", 
          "perspective", 
          "system", 
          "prices"
        ], 
        "name": "Cost effectiveness of sirolimus-eluting stents compared with bare metal stents in acute myocardial infarction", 
        "pagination": "19-29", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1007754942"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/bf03256139"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/bf03256139", 
          "https://app.dimensions.ai/details/publication/pub.1007754942"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-09-02T15:54", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_494.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/bf03256139"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf03256139'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf03256139'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf03256139'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf03256139'


     

    This table displays all metadata directly associated to this object as RDF triples.

    249 TRIPLES      21 PREDICATES      116 URIs      107 LITERALS      6 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/bf03256139 schema:about anzsrc-for:11
    2 anzsrc-for:1117
    3 schema:author Na8e640344ef84ac7b9bc0db115d8e664
    4 schema:citation sg:pub.10.2165/00129784-200606030-00003
    5 schema:datePublished 2009-03
    6 schema:datePublishedReg 2009-03-01
    7 schema:description BackgroundDrug-eluting stents have been shown to reduce the rate of repeat revascularization after percutaneous coronary intervention for acute myocardial infarction (AMI) as compared with bare metal stents (BMS). A few studies have reported the cost effectiveness of sirolimus-eluting stents (SES) in several countries, but none in the particular setting of AMI in France.ObjectivesTo assess the cost effectiveness of SES compared with BMS in a pre-specified subgroup of French patients with AMI in the randomized, multicentre TYPHOON trial.MethodsA prospective economic evaluation was conducted for the 337 patients in the TYPHOON trial who were enrolled in the French centres. In the TYPHOON trial, patients with AMI with ST-segment elevation less than 12 hours after the onset of chest pain were randomized to undergo percutaneous coronary intervention with either SES or BMS. Data on clinical outcomes and resource use were collected prospectively over a 1-year follow-up period (from October 2003 to October 2005). Unit costs were applied to the resource utilization data. The main outcome measure was the incremental cost-effectiveness ratio (ICER) for additional cost per target-vessel revascularization (TVR) avoided. The perspective of the study was the French healthcare system and costs were expressed in 2007 values.ResultsSES significantly reduced the rate of TVR (6.6% vs 22.2% with BMS, p < 0.0001). There was no difference in the rate of death, recurrent myocardial infarction or stent thrombosis after 1 year of follow-up between the SES and BMS groups. Mean index admission costs, including the angioplasty procedure, were increased by €1282 per patient in the SES group, mostly driven by the price of the SES. Mean follow-up costs were €140 per patient lower in the SES group. Mean aggregate 1-year costs showed a €1142 per-patient increase in the SES group compared with the BMS group. The ICER was €7321 per TVR avoided.ConclusionIn this pre-specified subgroup analysis of the TYPHOON trial, the use of SES in patients with AMI with ST-segment elevation less than 12 hours after the onset of chest pain reduced the rate of TVR compared with BMS. However, SES had a debatable ICER for the payer if it was based only on the specific benefit of TVR avoided.
    8 schema:genre article
    9 schema:isAccessibleForFree false
    10 schema:isPartOf N6dafdf5a70ad4b02b2c82080b84980bb
    11 Nb5bfc89ec8d043759874b3f7a82b68a3
    12 sg:journal.1031175
    13 schema:keywords BMS group
    14 BackgroundDrug
    15 ConclusionIn
    16 France
    17 French centers
    18 French healthcare system
    19 French patients
    20 ObjectivesTo
    21 Randomized
    22 SES group
    23 ST-segment elevation
    24 acute myocardial infarction
    25 additional cost
    26 admission costs
    27 analysis
    28 angioplasty procedures
    29 bare metal stents
    30 benefits
    31 center
    32 chest pain
    33 clinical outcomes
    34 coronary intervention
    35 cost
    36 cost effectiveness
    37 cost-effectiveness ratio
    38 countries
    39 data
    40 death
    41 differences
    42 economic evaluation
    43 effectiveness
    44 elevation
    45 evaluation
    46 follow
    47 group
    48 healthcare system
    49 hours
    50 increase
    51 incremental cost-effectiveness ratio
    52 index admission costs
    53 infarction
    54 intervention
    55 main outcome measures
    56 measures
    57 metal stents
    58 myocardial infarction
    59 onset
    60 outcome measures
    61 outcomes
    62 pain
    63 particular setting
    64 patients
    65 patients increases
    66 payers
    67 percutaneous coronary intervention
    68 period
    69 perspective
    70 pre-specified subgroup analysis
    71 pre-specified subgroups
    72 prices
    73 procedure
    74 prospective economic evaluation
    75 rate
    76 rate of TVR
    77 rate of death
    78 ratio
    79 recurrent myocardial infarction
    80 repeat revascularization
    81 resource use
    82 resource utilization data
    83 resultss
    84 revascularization
    85 setting
    86 sirolimus-eluting stents
    87 specific benefits
    88 stent thrombosis
    89 stents
    90 study
    91 subgroup analysis
    92 subgroups
    93 system
    94 target vessel revascularization
    95 thrombosis
    96 trials
    97 unit cost
    98 use
    99 use of SS
    100 utilization data
    101 values
    102 years
    103 schema:name Cost effectiveness of sirolimus-eluting stents compared with bare metal stents in acute myocardial infarction
    104 schema:pagination 19-29
    105 schema:productId N477e82b012054126b720693f2c0d0912
    106 N4b208747c6854b939e095d358fe3ebc0
    107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007754942
    108 https://doi.org/10.1007/bf03256139
    109 schema:sdDatePublished 2022-09-02T15:54
    110 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    111 schema:sdPublisher N81da749aaf6544c2ba1fc37a6cba09cf
    112 schema:url https://doi.org/10.1007/bf03256139
    113 sgo:license sg:explorer/license/
    114 sgo:sdDataset articles
    115 rdf:type schema:ScholarlyArticle
    116 N02a09fb4a7b7414cac0cf2ed80291302 rdf:first sg:person.01317466507.22
    117 rdf:rest N4a7930aed58843d4a95127703ed8152f
    118 N117f9c5f1a494933bd82647b561a5cc6 rdf:first sg:person.01015234324.86
    119 rdf:rest N7582ff71db5d43348265d03980cf82a3
    120 N477e82b012054126b720693f2c0d0912 schema:name dimensions_id
    121 schema:value pub.1007754942
    122 rdf:type schema:PropertyValue
    123 N4a7930aed58843d4a95127703ed8152f rdf:first sg:person.01132547050.16
    124 rdf:rest N92acfd06e4b9439696db244b9bffd8d3
    125 N4b208747c6854b939e095d358fe3ebc0 schema:name doi
    126 schema:value 10.1007/bf03256139
    127 rdf:type schema:PropertyValue
    128 N617a3239a10e43e0911cf6d391521a37 rdf:first sg:person.01147423204.29
    129 rdf:rest N6e638f2ca7374a22aaadd3aef5e213d4
    130 N6dafdf5a70ad4b02b2c82080b84980bb schema:volumeNumber 7
    131 rdf:type schema:PublicationVolume
    132 N6e638f2ca7374a22aaadd3aef5e213d4 rdf:first sg:person.01307107653.82
    133 rdf:rest Ndd79cc481a4043f082a4d9375349aee9
    134 N7582ff71db5d43348265d03980cf82a3 rdf:first sg:person.01340323437.03
    135 rdf:rest N617a3239a10e43e0911cf6d391521a37
    136 N81da749aaf6544c2ba1fc37a6cba09cf schema:name Springer Nature - SN SciGraph project
    137 rdf:type schema:Organization
    138 N8a577b4709d6459298107c452945f120 rdf:first sg:person.01327533357.46
    139 rdf:rest rdf:nil
    140 N92acfd06e4b9439696db244b9bffd8d3 rdf:first sg:person.01047345157.34
    141 rdf:rest N991e27faadbb45929e2488801a3efae2
    142 N991e27faadbb45929e2488801a3efae2 rdf:first sg:person.01133236474.84
    143 rdf:rest N117f9c5f1a494933bd82647b561a5cc6
    144 Na8e640344ef84ac7b9bc0db115d8e664 rdf:first sg:person.01012106505.90
    145 rdf:rest N02a09fb4a7b7414cac0cf2ed80291302
    146 Nb5bfc89ec8d043759874b3f7a82b68a3 schema:issueNumber 1
    147 rdf:type schema:PublicationIssue
    148 Ndd79cc481a4043f082a4d9375349aee9 rdf:first sg:person.0701250526.43
    149 rdf:rest N8a577b4709d6459298107c452945f120
    150 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    151 schema:name Medical and Health Sciences
    152 rdf:type schema:DefinedTerm
    153 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
    154 schema:name Public Health and Health Services
    155 rdf:type schema:DefinedTerm
    156 sg:journal.1031175 schema:issn 1175-5652
    157 1179-1896
    158 schema:name Applied Health Economics and Health Policy
    159 schema:publisher Springer Nature
    160 rdf:type schema:Periodical
    161 sg:person.01012106505.90 schema:affiliation grid-institutes:grid.413852.9
    162 schema:familyName Canoui-Poitrine
    163 schema:givenName Florence
    164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012106505.90
    165 rdf:type schema:Person
    166 sg:person.01015234324.86 schema:affiliation grid-institutes:grid.414295.f
    167 schema:familyName Carrié
    168 schema:givenName Didier
    169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01015234324.86
    170 rdf:type schema:Person
    171 sg:person.01047345157.34 schema:affiliation grid-institutes:grid.413235.2
    172 schema:familyName Armoogum
    173 schema:givenName Priscilla
    174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047345157.34
    175 rdf:type schema:Person
    176 sg:person.01132547050.16 schema:affiliation grid-institutes:grid.7429.8
    177 schema:familyName Alberti
    178 schema:givenName Corinne
    179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132547050.16
    180 rdf:type schema:Person
    181 sg:person.01133236474.84 schema:affiliation grid-institutes:None
    182 schema:familyName Cebrian
    183 schema:givenName Ana
    184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133236474.84
    185 rdf:type schema:Person
    186 sg:person.01147423204.29 schema:affiliation grid-institutes:grid.412116.1
    187 schema:familyName Teiger
    188 schema:givenName Emmanuel
    189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01147423204.29
    190 rdf:type schema:Person
    191 sg:person.01307107653.82 schema:affiliation grid-institutes:grid.413738.a
    192 schema:familyName Slama
    193 schema:givenName Michel
    194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307107653.82
    195 rdf:type schema:Person
    196 sg:person.01317466507.22 schema:affiliation grid-institutes:grid.412116.1
    197 schema:familyName Jeanblanc
    198 schema:givenName Grégoire
    199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317466507.22
    200 rdf:type schema:Person
    201 sg:person.01327533357.46 schema:affiliation grid-institutes:grid.412116.1
    202 schema:familyName Durand-Zaleski
    203 schema:givenName Isabelle
    204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327533357.46
    205 rdf:type schema:Person
    206 sg:person.01340323437.03 schema:affiliation grid-institutes:grid.50550.35
    207 schema:familyName Henry
    208 schema:givenName Patrick
    209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340323437.03
    210 rdf:type schema:Person
    211 sg:person.0701250526.43 schema:affiliation grid-institutes:grid.7429.8
    212 schema:familyName Spaulding
    213 schema:givenName Christian
    214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701250526.43
    215 rdf:type schema:Person
    216 sg:pub.10.2165/00129784-200606030-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028254639
    217 https://doi.org/10.2165/00129784-200606030-00003
    218 rdf:type schema:CreativeWork
    219 grid-institutes:None schema:alternateName Cordis (Johnson & Johnson), Waterloo, Belgium
    220 schema:name Cordis (Johnson & Johnson), Waterloo, Belgium
    221 rdf:type schema:Organization
    222 grid-institutes:grid.412116.1 schema:alternateName Assistance Publique - Hopitaux de Paris (AP-HP), Henri Mondor Hospital, EA 4393, Paris 12 Medical School, Créteil, France
    223 Service de Sante Publique, Hôpital Henri Mondor, 51, Avenue du Maréchal de Lattre de Tassigny, 94010, Créteil, Cedex, France
    224 schema:name Assistance Publique - Hopitaux de Paris (AP-HP), Henri Mondor Hospital, EA 4393, Paris 12 Medical School, Créteil, France
    225 Service de Sante Publique, Hôpital Henri Mondor, 51, Avenue du Maréchal de Lattre de Tassigny, 94010, Créteil, Cedex, France
    226 rdf:type schema:Organization
    227 grid-institutes:grid.413235.2 schema:alternateName AP-HP, Unit of Clinical Epidemiology, Robert Debre Hospital, Paris, France
    228 schema:name AP-HP, Unit of Clinical Epidemiology, Robert Debre Hospital, Paris, France
    229 rdf:type schema:Organization
    230 grid-institutes:grid.413738.a schema:alternateName AP-HP, Antoine Beclere Hospital, Paris 11 Medical School, Paris Sud University, Clamart, France
    231 schema:name AP-HP, Antoine Beclere Hospital, Paris 11 Medical School, Paris Sud University, Clamart, France
    232 rdf:type schema:Organization
    233 grid-institutes:grid.413852.9 schema:alternateName Université de Lyon, Hospices Civils de Lyon, Lyon, France
    234 schema:name Assistance Publique - Hopitaux de Paris (AP-HP), Henri Mondor Hospital, EA 4393, Paris 12 Medical School, Créteil, France
    235 Université de Lyon, Hospices Civils de Lyon, Lyon, France
    236 rdf:type schema:Organization
    237 grid-institutes:grid.414295.f schema:alternateName Rangueil Hospital, Toulouse, France
    238 schema:name Rangueil Hospital, Toulouse, France
    239 rdf:type schema:Organization
    240 grid-institutes:grid.50550.35 schema:alternateName AP-HP, Lariboisiere-Saint Louis Hospital, Paris 7 Medical School, Denis Diderot University, Paris, France
    241 schema:name AP-HP, Lariboisiere-Saint Louis Hospital, Paris 7 Medical School, Denis Diderot University, Paris, France
    242 rdf:type schema:Organization
    243 grid-institutes:grid.7429.8 schema:alternateName INSERM U 907, Paris, France
    244 INSERM, Paris, France
    245 schema:name AP-HP, Cochin Hospital, Paris Descartes University, Paris, France
    246 AP-HP, Unit of Clinical Epidemiology, Robert Debre Hospital, Paris, France
    247 INSERM U 907, Paris, France
    248 INSERM, Paris, France
    249 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...